hotspot -WSS

hotspot

author：leisure time 2025-09-27 22:49:47 - browse：13385

The Novartis booth at ESMO in Madrid. — The Novartis booth at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Results presented Monday could expand the use of a Novartis therapy for metastatic prostate cancer, moving it from a treatment used after chemotherapy to one with demonstrated benefits beforehand as well.

The Phase 3 data, highlighted in a prime session here at the annual meeting of the European Society for Medical Oncology, also amount to another win for cancer therapies designed to deliver radiation directly to tumor cells. It’s a field that Novartis has poured investments into, and that is attracting interest from other pharma companies.

The trial, called PSMAfore, enrolled patients with a type of metastatic prostate cancer whose disease had started to progress after taking a drug known as an androgen receptor pathway inhibitor, or ARPI. Patients were randomized to either receive a different ARPI or Novartis’ therapy, Pluvicto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Neuroscience’s long legacy of racism

WSS

5 to watch: Tech startups trying to solve health care's staffing crisis

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

Security flaws in third

Fatty liver disease was alleviated by Lilly’s ‘triple

Plastic surgeons increase patient psychiatric screenings

hotspot

hotspot

focus

The high cost of giving birth even with insurance

Beware reading your test results before your doctor does

Dobbs anniversary: the lost opportunity of abortion as health care

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Use doctors trained outside the U.S. to ease the physician shortage

After affirmative action ruling, medical educators look to 'holistic review'

Health AI adoption puts security, privacy startups on investors' radar

Medical records are filled with copy

Beware reading your test results before your doctor does

leisure time

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

Creating egg and sperm cells from stem cells raises ethical issues

SCOTUS questions limit to govt efforts to fight misinformation

5 to watch: Tech startups trying to solve health care's staffing crisis

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

entertainment

knowledge

hotspot

knowledge